MRTX 0.00 Stock Price Mirati Therapeutics, Inc.
Range: | 27.3-64.41 | Vol Avg: | 1778618 | Last Div: | 0 | Changes: | -0.1 |
Beta: | 0.77 | Cap: | 4.12B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Mon Jul 15 2013 | Empoloyees: | 587 |
CUSIP: | 60468T105 | CIK: | 0001576263 | ISIN: | US60468T1051 | Country: | US |
CEO: | Dr. Charles M. Baum M.D., Ph.D. | Website: | https://www.mirati.com |
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.